Pharmacogenetic Variant Reporting May Increase Utility of Clinical Exome But Barriers Exist | GenomeWeb

NEW YORK (GenomeWeb) – Extracting pharmacogenetic variants from exome or genome sequencing data is feasible and generates more clinically useful information than current PGx chips, according to a recent study by researchers at the National Institutes of Health's National Human Genome Research Institute.

But although this capability may enhance the utility of clinical exome and genome tests, calling PGx variants from sequence data is still technically difficult and many clinicians resist using pharmacogenetic information when prescribing drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.